PROF.DR. FİLİZ ÇAY ŞENLER    
Adı : FİLİZ
Soyadı : ÇAY ŞENLER
E-posta : senler@medicine.ankara.edu.tr
Tel : 0.312- 595 7115
Ünvan : PROF.DR.
Birim : TIP FAKÜLTESİ
Bölüm : DAHİLİ TIP BİLİMLERİ BÖLÜMLERİ
Kişisel Akademik Bilgiler

1.Cay-Senler F, Yavuzsen T, Turhal S, Akman T, Komurcu S, Cehreli R,Ozyilkan
O. Perspectives and practical applications of medical oncologists on defensive
medicine (SYSIPHUS study): a study of the Palliative Care
Working Committee of the Turkish Oncology Group (TOG)Med Oncol
(2015) 32: 106, DOI 10.1007/s12032-015-0555-5. 

2. Tanriverdi O, Yavuzsen T, Akman T, Cay Senler F, Yapar Taskoylu B, Turhal S, Komurcu S, Cehreli R, Yaren A, Ozyilkan O.  The Perspective of Non-oncologist Physicians on Patients with Metastatic Cancer and Palliative Care (ALONE Study):A Study of the Palliative CareWorking Committee of the Turkish Oncology Group (TOG). J Canc Educ 2015. DOI 10.1007/s13187-015-0794-3.

3. Tanrıverdı O, Yavuzsen T, Turhal S, Kılıc D, Yalcın S, Ozkan A, Uzunoglu S, Uysal-Sonmez O, Akman T, Aktas B, Ulger S, Babacan T, Komurcu S, Yaren A.Cay-Senler F. Depression and socio-economical burden are more common in primary caregivers of patients who are not aware of their cancer: TURQUOISE Study by the Palliative Care Working Committee of the Turkish Oncology Group (TOG). European Journal of Cancer Care, 2015. DOI: 10.1111/ecc.12315.  

4. Turker I, Komurcu S, Arıcan A, Doruk H, Ozyılkan O, Coskun HS, Colak D, Uçgul Cavusoglu E, Ata A, Sezer A, Yesil Cınkır H, Cay Senler F, Arpacı F. Investigational tests and treatments performed in terminal stage cancerpatients in two weeks before death: Turkish oncology group (TOG) study.Med Oncol (2014) 31:1- 6. DOI 10.1007/s12032-014-0350-8.  

5. Urun Y, Akbulut H, Demirkazik A, Cay Senler F, Utkan G, Onur H, Icli F.  Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members. J BUON 2013; 18(2): 511-515.ISSN: 1107-0625.  

6. Çay Şenler F, Çakmakçı Ş, Arıkan Akan Ö,  Demirkazık A, Akbulut H, İçli F.Characteristics Of Oropharyngeal Candida And Bacterial Colonization in Cancer Patients. UHOD 2012;22(2): 113-119. DOI 10.4999/uhod.11080.


 

7. Urun Y, Utkan G, Altundag K, Arslan O, Onur H, Arslan UY, Kocer  M, Dogan I, Senler FC, Yalcin B, Demirkazik A, Akbulut H, Icli F. ABO and Rh blood groups frequency in women with HER2 positive breast cancer. Journal of BUON 17: 457-4 60, 2012.  

8. Icli F, Akbulut H, Onur H, Yalcin B, Demirkazık A, Senler FC.Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up). Breast. 2011:20:155-157.

9. Dincol D, Buyukcelik A, Doğan M, Akbulut H, Samur M, Demirkazık A, Cay Senler F, Onur H, Icli F. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP. Medical Oncology 2009. DOI 10.1/7s12032-009-9313-x. 

 

10. Sencan O, Buyukcelik A, Yalcin B, Boruban MC, Akbulut H, Demirkazik A, Senler FC, Onur H, Icli F. The symptomatic benefit (the clinical benefit response) from the second –line chemotherapy in patients with advanced gastric adenocarcinoma. European Journal of Cancer Care 2008; 17: 26-32. 

 11. Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isıkdogan A, Onur H, Cay F, Buyukcelik A.  Low Molecular Weight Heparin (LMWH) increases the efficacy of Cisplatinum plus Gemcitabine Combination in Advanced Pancreatic Cancer. Journal of Surgical Oncology 2007; 93: 507-512.

12. Kayacan O, Karnak D, Beder S, Gullu E, Tutkak H, Cay Senler F,  Koksal D.  Impact of TNF- and IL-6 Levels on Development of Cachexia in Newly Diagnosed NSCLC Patients.  American Journal of Clinical Oncology 2006; 29: 328-335. 

   

13. Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coskun S, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Buyukcelik A, Boruban C, Onur H, Zengin N, Sak SD. Cispatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer 2005; 92: 639-644.

 

14. Dinçol D, Samur M, Pamir A, Şencan O, Akbulut H, Yalçın B, Onur H, Demirkazık A, Çay Şenler F, İçli F. Prospective randomised comparison of morning versus night daily single subcutaneous administration of Granulocyte-Macrophage-Colony- Stimulating Factor in patients with soft tissue or bone sarcom. Cancer 2000;88: 2033-2036.

 

15. Arıcan A, Dinçol D, Akbulut H, Onur H, Demirkazık A, Çay F, İçli F. Clinicopathologic features and prognostic factors of primary extranodal non-Hodgkin’s lymphoma in Turkey. American Journal of Clinical Oncology 1999;22(6): 587-592. (SCI) 

 

16. Dinçol D, Akbulut H, İçli F, Samur M, Karaoğuz H, Çay F, İçli F. Results of the cyclophosphamide, adriamycine, vincristine, prednisolon (CHOP) ± bleomycin treatment and evaluation of prognostic factors in aggresive lymphomas in Turkey. Oncology 1997; 54: 376-379.  

 

17. İçli F, Karaoğuz H, Akbulut H, Dinçol D, Demirkazık A, Çay F. A phase II study of modified combination of etoposide, doxorubicin and  cisplatin for patients with advanced gastric carcinoma. Journal of Surgical Oncology 1997; 64: 318-323. 

 

18.İçli F, Karaoğuz H, Hastürk S, Kurt B, Akbulut H, Demirkazık A, Dinçol D, Çay F, Akyar S. Two dose level of ifosfamide in malignant mesothelioma. Lung Cancer 1996; 15: 207-231. 

 

19. Dinçol D, İçli F, Karaoğuz H, Çay F, Arıcan A, Demirkazık A, Akbulut H. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin’s lympoma. Acta Oncologica 1995; 43: 973-940. 

 

 ULUSLARARASI İNDEKSLERDE KAYITLI OLMAYAN HAKEMLİ DERGİLERDE YER ALAN YAYINLAR

1. Urun Y, Utkan G, Yalcin B, Akbulut H, Onur H, Oztuna DG, Senler FC, Demirkazik A, Icli F. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer. Experimental Oncology 2015;37(1):53- 7.

2. Urun Y, Ozdemir NY, Utkan G, Akbulut H, Savas B, Oksuzoglu B, Oztuna DG, Dogan I, Yalcin B, Senler FC, Onur H, Demirkazik A,Zengin N, Icli F. ABO and Rh blood groups and Risk of Colorectal Adenocarcinoma. Asian Pacific Journal of Cancer Prevention APJCP 2012; 13(12):6097- 100. DOI:10.7314/APJCP.2012.13.12.6097.

 3. Yalcin B, Akbulut H, Buyukcelik A, Sencan O, Demirkazik A, Onur H, Cay Senler F, Dincol D, Icli F. The Effects of Chronomodulated Therapy with 5-Fluorouracil (5Fu) and Folinic Acid (Fa) on the Toxicity and Qality of Life in Patients with Advanced Gastrik Cancer. Biological Rhythm Research 2004; 35: 259-268.

4. Arda B, Aksit B, Calisir HC, Platin N, Cay Senler F, Bokesoy I, Atasoy T, Demirdoven I, Sayek F. Chapitre 4.  How sufficient are the ethics committees? Results of a pilot study in Turkey. Journal International de Bioéthique 2004; 5(4):61-6.DOI:10.3917/jib.154.0061

B5. Dinçol D, Arıcan A. Aydın F, Samur M, Willke A, Akbulut H, Pamir A, Çay F, İçli F. A comparison of imipenem monotherapy versus cefoperazone/sulbactam plus amikacin combination treatment in febril netropenic cancer patients. The Cancer Journal 1998; 11: 89- 93.

 

6.Demirkazık A, Dinçol D, Hastürk S, Arıcan A, Karaoğuz H, Çay F, İçli F. Diagnostic value of ferritin in the differantial diagnosis of malignant effusions. Cancer Biochemistry Biophysic 1997; 16: 243-251. 

 

 ULUSAL DERGİLERDE YER ALAN ARAŞTIRMA MAKALELERİ VE DERLEMELER

1.Çay Şenler F. Onkoloji Biriminde Çalışanlarda Tükenmişlik. Türkiye Klinikleri Psikiyatri Psikoonkoloji Kavşağı Özel Sayısı 2014; 7(4):59- 63.

 

2. Ünsal D, Çay Şenler F. Küçük hücreli akciğer kanseri olan yaşlı hastalarda tedavi. Tüberküloz ve Toraks Dergisi 2010; 58(1): 108-114.

 

3. Çay Şenler F. Küçük Hücreli Akciğer Kanserinde Kemoterapi. Türkiye Klinikleri Tıbbi Onkoloji Akciğer Kanseri Özel Sayısı. 2008, 2(1): 81-90.

 

4. Çay Şenler F.Kanserde Kemik Komplikasyonları ve Önlenmesi. Türkiye Klinikleri Cerrahi Tıp Bilimleri Acil Tıp Onkolojik Aciller Özel Sayısı. 2006, 2(12): 88-92.

 

5. Doğan M, Çay Şenler F. Akciğer Kanserinde Kemoprevensiyon. Türkiye Klinikleri Cerrahi Tıp Bilimleri Göğüs Cerrahisi Akciğer Kanseri Özel Sayısı. 2006, 2(33): 72-76.

 

6. Yalçın B, Büyükçelik A, Çay Şenler F, Utkan G, Tek İ, Doğan M, Doruk H, Demirkazık A, Akbulut A, İçli F. Frequency of symptoms in patients with advanced cancer. Turkish Journal of Cancer 2005; 35(4): 177-180.

7. Yalçın B, Çay Şenler F, Büyükçelik A, Utkan G, Tek İ, Doruk H, Akbulut A, İçli F. The opinions of the cancer patients obout pain management: A questionnaire study. Turkish Journal of Cancer 2004; 34(3): 114-117.

 

8. Samur M, Çay Şenler F, Akbulut H, Pamir A, Arıcan A. Kanser tanısı almış hastaların bilgilendirilme durumu: Hekim ve hekim adaylarının yaklaşımları hakkında Ankara Üniversitesi Tıp Fakültesi İbni Sina Hastanesi’nde yapılan sınırlı bir araştırmanın sonuçları. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2000;53(3): 161-166.

 

9. Akbulut H, Dinçol D, Aydıntuğ O, İçli F, Karaoğuz H, Demirkazık A, Çay F, Aydın F. The prognostic significance of flow cytometric cellular DNA content determination in patiens with colorectal carcinoma. Turkish Journal of Cancer 1998; 2882): 51- 57.